30 Jan, 2020, 17:31 ET
NEW YORK, Jan. 30, 2020 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, California and Georgia, announces an investigation of ResMed Inc. (NYSE: RMD) ("ResMed," or the "Company").
If you own RMD shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
1500 Broadway, 16th Floor
New York, NY 10036
The investigation focuses on possible breaches of fiduciary duty and violations of federal securities laws by ResMed's Board of Directors for the alleged dissemination of materially false and misleading information in connection with the Company's operations.
ResMed recently paid $37.5 million to settle claims by the U.S. Justice Department relating to whistleblower complaints concerning alleged kickbacks to doctors for inducing prescriptions for its continuous positive airway pressure ("CPAP") machines to patients suffering from sleep apnea.
WeissLaw is investigating whether ResMed's Board breached its fiduciary duties to the Company and its shareholders by (1) misrepresenting and/or failing to disclose material information about the Company, its business practices, and its customer-base; and (2) engaging in certain business practices that would expose the Company to liability and regulatory scrutiny.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]
SOURCE WeissLaw LLP
Share this article